Pharma channel feed – Endpoints News

Pharma channel feed

Merck KGaA splurges $230M on its pipeline, paying Vertex for a slate of early-stage cancer drugs

9 years ago

A hungry Takeda continues deal spree with $125M T cell pact, option to buy

9 years ago

Struggling Sarepta bounces back as analysts cheer the first trickle of revenue for DMD drug

9 years ago

J&J Innovation expands its biotech incubator JLABS into Manhattan

9 years ago

Fresh from grabbing Shire’s mRNA work, RaNA discloses a $51M raise

9 years ago

Kite lines up a JV in China while Daiichi Sankyo strikes $250M-plus deal to launch CAR-T drug in Japan

9 years ago

Allergan bags two new deals, takes option to buy Lysosomal Therapeutics and pays $50M for microbiome pact

9 years ago

Novartis adds to its cardio pipeline with $1.65B Ionis pact

9 years ago

Analysts assess the damage — and next steps — after Regeneron/Sanofi get slammed in court

9 years ago

J&J grabs an option to buy a NASH drug in latest string of biotech deals

9 years ago

M&A inflation just pushed the average biopharma valuation to a scary new peak

9 years ago

New drug price controversy looms as Biogen stuns payers with Spinraza's $750K sticker — analyst

9 years ago

Biogen, Ionis win FDA OK for spinal muscular atrophy drug Spinraza

9 years ago

WSJ's editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters

9 years ago

ChemoCentryx grabs $50M upfront, adds development partnership with Vifor

9 years ago

The Senate dissects Martin Shkreli's scheme to grab a $1B windfall

9 years ago

Is biopharma’s Midas man Vivek Ramaswamy building a new IPO vehicle with Dermavant deal?

9 years ago

Incyte antes up $200M — promises billions more — to launch a bispecific development deal with Merus

9 years ago

Bristol-Myers doubles down on PsiOxus in $936M-plus “armed” oncolytic virus deal

9 years ago

Editas fires back at CRISPR/Cas9 rivals, bagging an exclusive license to a tech upgrade

9 years ago

Celgene, Versant back a biotech merger, building an antibody pipeline and lining up for the clinic

9 years ago

CRISPR/Cas9 players create an IP alliance as the war with Editas heats up

9 years ago

In a first, AstraZeneca gains rights to an antisense KRAS drug in $165M Ionis deal

9 years ago

Gilead’s rep takes another punishing blow as a bad, no good, awful year just got worse

9 years ago

First page Previous page 336 337 338339340 341 342 Next page Last page